Cited by 3,848Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel, Walde, David, Wolff, Robert A., Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Open this paper in CoChat — free account

Abstract

Purpose: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. Results: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. Conclusion: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.9525

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Flagged first, then by citations

Show all 49 references

1 of the 49 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 1,008

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Cardiovascular Complications of Cancer Therapy
Chang, H., Moudgil, R., Scarabelli, T. M., Okwuosa, T. M., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1096 · Cited by 394
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G. M., & Cagnoni, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2610 · Cited by 385
Self-citation
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Infante, J. R., Somer, B. G., Park, J. O., Li, C., Scheulen, M. E., Kasubhai, S. M., Oh, D., Liu, Y., Redhu, S., Steplewski, K. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 369
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
Self-citation
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Laheru, D. A., Lutz, E. R., Burke, J., Biedrzycki, B. A., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J. J., Le, D. T., Sugar, E. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors
Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 334
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S., Gladkov, O. A., Holcombe, R. F., Korn, R. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 339
Focal adhesion signaling and therapy resistance in cancer
Eke, I., & Cordes, N. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 339
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1412 · Cited by 339
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
Provenzano, P. P., & Hingorani, S. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.569 · Cited by 337
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J. P., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T. R., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 319
Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance
Shi, Z., Peng, X.-X., Kim, I., Shukla, S., Si, Q.-S., Robey, R. W., Bates, S. E., Shen, T., Ashby, C. R., Fu, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2686 · Cited by 315
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H. P., Hoffman, J. P., Konski, A. A., Benson, A. B., Macdonald, J. S., Rich, T. A., & Willett, C. G. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1630-6 · Cited by 311
Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127
Dragovich, T., McCoy, S., Fenoglio‐Preiser, C. M., Wang, J., Benedetti, J., Baker, A. F., Hackett, C. B., Urba, S. G., Zaner, K. S., Blanke, C. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1316 · Cited by 309
Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer
Butturini, G. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.17 · Cited by 309
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Kim, E. J.-H., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N., Khan, G. N., Blau, J., Craig, R. A., Balis, U. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1269 · Cited by 307
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y.-C., & Lawrence, T. S. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1953 · Cited by 302
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 310
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 315
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
Colucci, G., Labianca, R., Costanzo, F. D., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 303
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 301
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Sinn, M., Bahra, M., Liersch, T., Gellert, K., Messmann, H., Bechstein, W. O., Waldschmidt, D., Jacobasch, L., Wilhelm, M., Rau, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6463 · Cited by 299
Therapeutic Advances in Pancreatic Cancer
Paulson, A. S., Cao, H. S. T., Tempero, M. A., & Lowy, A. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.078 · Cited by 292
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 289
Self-citation
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Current status and progress of pancreatic cancer in China
Lin, Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i26.7988 · Cited by 285
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M. S., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 285
Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary Cilia
Seeley, E. S., Carrière, C., Goetze, T., Longnecker, D. S., & Korc, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1290 · Cited by 285
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., & Bar‐Sela, G. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.513802 · Cited by 282
Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer
Abou‐Alfa, G. K., Letourneau, R., Harker, W. G., Modiano, M., Hurwitz, H. I., Tchekmedyian, N. S., Feit, K., Ackerman, J., Jager, R. L. D., Eckhardt, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0201 · Cited by 281
Chemotherapy for pancreatic cancer
Springfeld, C., Jäger, D., Büchler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.02.025 · Cited by 297
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth
Porembka, M. R., Mitchem, J. B., Belt, B. A., Hsieh, C., Lee, H.-M., Herndon, J. M., Gillanders, W. E., Linehan, D. C., & Goedegebuure, P. S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1178-0 · Cited by 278
EGFR Targeting of Solid Tumors
Rocha‐Lima, C., Soares, H. P., Raez, L. E., & Singal, R. (2007) · Cancer Control · doi:10.1177/107327480701400313 · Cited by 276
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
Rajeshkumar, N. V., Oliveira, E. D., Ottenhof, N. A., Watters, J., Brooks, D. G., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
Monti, D., Mitchell, E. P., Bazzan, A. J., Littman, S. J., Zabrecky, G. P., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029794 · Cited by 274
Small Molecule Inhibitors of CXCR4
Debnath, B., Xu, S., Grande, F., Garofalo, A., & Neamati, N. (2013) · Theranostics · doi:10.7150/thno.5376 · Cited by 274
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267
The Pathology and Genetics of Metastatic Pancreatic Cancer
Yachida, S., & Iacobuzio–Donahue, C. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.413 · Cited by 269
Common pitfalls in statistical analysis: Clinical versus statistical significance
Ranganathan, P., Pramesh, C. S., & Buyse, M. E. (2015) · Perspectives in Clinical Research · doi:10.4103/2229-3485.159943 · Cited by 268
A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer
Chugh, R., Sangwan, V., Patil, S. P., Dudeja, V., Dawra, R. K., Banerjee, S., Schumacher, R. J., Blazar, B. R., Georg, G. I., Vickers, S. M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004334 · Cited by 268
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
Patel, G. K., Khan, M. A., Bhardwaj, A., Srivastava, S. K., Zubair, H., Patton, M. C., Singh, S., Khushman, M. M., & Singh, A. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.18 · Cited by 268
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 264
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment
Kim-Fuchs, C., Le, C. P., Pimentel, M. A., Shackleford, D., Ferrari, D., Angst, E., Hollande, F., & Sloan, E. K. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.02.019 · Cited by 287
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 264
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda, M. N., & Niu, J. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s88023 · Cited by 260
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
Khoja, L., Backen, A. C., Sloane, R. A. S., Menasce, L. P., Ryder, W. D. J., Krebs, M., R Board, Clack, G., Hughes, A. M., Blackhall, F. H., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.545 · Cited by 266
Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer
Schellenberg, D. D., Kim, J., Christman-Skieller, C., Chun, C. L., Columbo, L. A., Ford, J. M., Fisher, G. A., Kunz, P. L., Dam, J. V., Quon, A. S. W., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.006 · Cited by 253
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 273
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
Spano, J., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H. S., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y. K., Bycott, P. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60661-3 · Cited by 250
Screening for Pancreatic Cancer: Why, How, and Who?
Poruk, K. E., Firpo, M. A., Adler, D. G., & Mulvihill, S. J. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31825ffbfb · Cited by 249
Comparative Effectiveness and Health Care Spending — Implications for Reform
Weinstein, M. C., & Skinner, J. (2010) · New England Journal of Medicine · doi:10.1056/nejmsb0911104 · Cited by 247
Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma
Cohen, S. J., Alpaugh, R. K., Palazzo, I., Meropol, N. J., Rogatko, A., Xu, Z., Hoffman, J. P., Weiner, L. M., & Cheng, J. D. (2008) · Pancreas · doi:10.1097/mpa.0b013e31816618ce · Cited by 244
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Christenson, E. S., Jaffee, E. M., & Azad, N. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30795-8 · Cited by 245
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 249
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B. H., Copple, I. M., Williams, S. J., Owen, A., Neoptolemos, J. P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-37 · Cited by 243
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 251
Tumor angiogenesis and anti‑angiogenic gene therapy for cancer (Review)
Li, T., Kang, G., Wang, T., & Huang, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8733 · Cited by 253
Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
Philip, P. A., Mooney, M., Jaffe, D., Eckhardt, G., Moore, M. J., Meropol, N. J., Emens, L. A., O'Reilly, E. M., Korc, M., Ellis, L. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9022 · Cited by 240
Self-citation
Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 245
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codó, P., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 242
Overcoming drug resistance in pancreatic cancer
Long, J., Zhang, Y., Yu, X., Yang, J., LeBrun, D. G., Chen, C., Yao, Q. C., & Li, M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.566216 · Cited by 241
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 239
An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network
Li, Y., Xie, P., Lu, L., Wang, J., Diao, L., Liu, Z., Guo, F., He, Y., Liu, Y., Huang, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00299-9 · Cited by 234
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
Buck, E. A., Eyzaguirre, A., Brown, E., Petti, F., McCormack, S., Haley, J. D., Iwata, K. K., Gibson, N. W., & Griffin, G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0166 · Cited by 234
Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells
Thoennissen, N. H., Iwanski, G. B., Doan, N., Okamoto, R., Lin, P. W., Abbassi, S., Song, J. H., Yin, D., Toh, M., Xie, W. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0536 · Cited by 235
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
Stokes, J. B., Adair, S. J., Slack‐Davis, J. K., Walters, D. M., Tilghman, R. W., Hershey, E. D., Lowrey, B. T., Thomas, K. S., Bouton, A. H., Hwang, R. F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0261 · Cited by 233
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J. E., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 235
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 247
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect
Matsumura, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.05.008 · Cited by 230
Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma
Narayanan, G., Hosein, P. J., Arora, G., Barbery, K. J., Froud, T., Livingstone, A. S., Franceschi, D., Lima, C. M. R., & Yrizarry, J. M. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.09.012 · Cited by 228
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer
Lü, J., Eppler, S., WOLF, J., Hamilton, M., Rakhit, A. K., Bruno, R., & Lum, B. L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.007 · Cited by 223
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer
Wang, D., Luo, H., Qiu, M., Wang, Z., Zhang, D.-S., Wang, F.-H., Li, Y.-H., & Xu, R. (2012) · Medical Oncology · doi:10.1007/s12032-012-0226-8 · Cited by 227
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
Gonçalvès, A., Gilabert, M., François, É., Dahan, L., Perrier, H., Lamy, R., Ré, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 222
Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
Wang, P., Chen, L., Zhang, J., Chen, H., Fan, J., Wang, K., Luo, J., Chen, Z., Meng, Z., & Liu, L. (2013) · Oncogene · doi:10.1038/onc.2012.598 · Cited by 224
Autophagy in the physiological endometrium and cancer
Devis, L., Eritja, N., Davis, M. L., Matías‐Guiu, X., & Llobet‐Navàs, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1752548 · Cited by 232
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
Wilson, M. K., Karakasis, K., & Oza, A. M. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70375-4 · Cited by 230
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W. M., Roesli, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4038 · Cited by 228
Pancreatic Stellate Cells and Pancreatic Cancer Cells: An Unholy Alliance
Vonlaufen, A., Phillips, P. A., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1132 · Cited by 223
Self-citation
Advanced-stage pancreatic cancer: therapy options
Werner, J., Combs, S. E., Springfeld, C., Hartwig, W., Hackert, T., & Büchler, M. W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.66 · Cited by 220
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Chiorean, E. G., & Coveler, A. L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 217
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 214
Pancreatic cancer: molecular pathogenesis and new therapeutic targets
Wong, H. H., & Lemoine, N. R. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.89 · Cited by 215
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells
Li, T., Ling, Y., Goldman, I. D., & Perez-Soler, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2923 · Cited by 214
Survival comparison between glioblastoma multiforme and other incurable cancers
Tran, B., & Rosenthal, M. A. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.09.004 · Cited by 220
Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Donahue, T. R., Tran, L. M., Hill, R., Li, Y., Kovochich, A., Calvopina, J. H., Patel, S. G., Wu, N., Hindoyan, A. A., Farrell, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1539 · Cited by 212
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222

Authors: Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W.
Affiliations: Norton Healthcare (US)
From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder...
ORCID: Moore, Malcolm J.
Goldstein, David
Hamm, John
Hecht, Joel R.
Au, Heather J.
Wolff, Robert A.
Ding, Keyue
Clark, Gary
Parulekar, Wendy
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2007-05-20
Volume: 25
Issue: 15
Pages: 1960-1966
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2006.07.9525
OpenAlex: W2158134441
Cited by: 3,848
References: 49
Citations by year: 2026: 45 · 2025: 62 · 2024: 123 · 2023: 113 · 2022: 129 · 2021: 178 · 2020: 159 · 2019: 170 · 2018: 204 · 2017: 217 · 2016: 242 · 2015: 275 · 2014: 274 · 2013: 251 · 2012: 268
FWCI: 133.78
Type: journal article
Language: en
Update notices: new_edition (2023-10-17)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: erlotinib, gemcitabine, advanced pancreatic cancer, targeted therapy, overall survival, progression-free survival, metastatic pancreatic cancer, combination chemotherapy, adverse events
MeSH terms: Erlotinib Hydrochloride, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Double-Blind Method, Female, Humans, International Agencies, Male, Middle Aged, Pancreatic Neoplasms, Placebos, Prognosis, Quinazolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks